Resveratrol as a Preventive Treatment of OHSS (RES-OHSS)

IVI Madrid

Status and phase: Completed; Phase 3

Conditions: Infertility

Treatments: Drug: Placebo; Drug: Resveratrol

Study type: Interventional

Funder types: Other

Identifiers

NCT03446625

1401-MAD-004-IO

Details and patient eligibility

About

Evaluation of resveratrol treatment oh ovarian hyperstimulation syndrome in egg donors

Full description

Randomized clinical trial to evaluate the role of resveratrol in preventing ovarian hyperstimulation syndrome by reducing VGEF expression and estradiol production, imporving hemoconcentration and symptomathology of this condition

Enrollment: 70 patients

Sex: Female

Ages: 18 to 35 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Number of follicles greater than 12 mm after ovarian stimulation
• Number of retrieved oocytes greater than 21

Exclusion criteria

• >35 years-old
• PCOS
• Endometriosis
• Systemic pathology
• Positive serologies for HBV, HBC and HIV
• Abnormal karyotype

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

70 participants in 2 patient groups, including a placebo group

Resveratrol

Experimental group

Description:

Resveratrol will be administered orally at the dose of 2 g/day for 9 days, starting on the day of ovulation triggering.

Treatment:

Drug: Resveratrol

Drug: Placebo

Control

Placebo Comparator group

Description:

Placebo treatment will be administered for 9 days, starting on the day of ovulation triggering.

Treatment:

Drug: Resveratrol

Drug: Placebo